NCT02161796View on ClinicalTrials.gov

A Study to Evaluate the Dose-proportionality and Effects of FG-4592 in Healthy Young and Elderly Male and Female Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
PK for FG-4592Healthy Subjects
Interventions
DRUG

FG-4592

Oral

DRUG

Placebo

Oral

Trial Locations (1)

14050

Parexel International GmbH, Berlin

Sponsors

Collaborators (1)

FibroGen
All Listed Sponsors
collaborator

FibroGen

INDUSTRY

lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT02161796 - A Study to Evaluate the Dose-proportionality and Effects of FG-4592 in Healthy Young and Elderly Male and Female Subjects | Biotech Hunter | Biotech Hunter